ArticleJournal of gastrointestinal cancer2026
The Lymph Node Ratio as a Predictive Biomarker for Individualized Benefit from Adjuvant Chemotherapy in Gastric Cancer: A Retrospective Cohort and Causal Machine Learning Study.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundOptimizing adjuvant chemotherapy (AC) for gastric cancer (GC) remains challenging due to patient heterogeneity. While the lymph node ratio (LNR) is a known prognostic factor, its role in predicting individualized AC benefit remains underexplored. This study aimed to leverage causal machine learning to explore LNR's role for personalized treatment.
methodsWe conducted a retrospective cohort study of 2,748 patients undergoing radical gastrectomy (2007-2017, re-staged by AJCC 8th edition). While the full cohort provided a demographic overview, analytic models focused on untreated Stage IB patients (n = 325) for prognostic factors, and Stage II-III patients (n = 825) for AC benefit estimation using a Causal Forest model with out-of-bag (OOB) predictions. Propensity score matching (PSM) was employed to mitigate treatment allocation bias.
resultsAC benefit was highly heterogeneous. In Stage IB, lymphovascular invasion (LVI) and elderly age were independent prognostic factors. Strikingly, the Causal Forest model (Area Under the Uplift Curve = 31.08) identified LNR as the most dominant predictor of AC benefit. Subgroup Cox interaction analysis within the PSM cohort (n = 434) confirmed a highly significant threshold effect (P for interaction < 0.001): AC significantly reduced mortality in the High LNR (> 0.25) group (HR = 0.41, P = 0.016), while showing potential harm in the Low LNR (< 0.1) group (HR = 2.58, P = 0.015). The top 20% of predicted beneficiaries achieved an Absolute Risk Reduction (ARR) of 21.59%, corresponding to a Number Needed to Treat (NNT) of 4.63.
conclusionsLNR is identified as a robust predictive biomarker for AC benefit in GC. This exploratory causal inference framework can help personalize treatment decisions, representing a valuable approach to complement clinical guidelines. To facilitate clinical application, an exploratory web-based decision support tool was developed.
Indexed as
Identifiers
42631885What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.